Yvonne Diaz, Director, Global Media Relations and Social Media at EY, shared on X:
“Is this the moment we start to see more of the promise of liquid biopsies?
A common theme across this morning’s NSCLC presentations at ESMO26 is early ctDNA clearance, sometimes within just 3–4 weeks.
Could this mean more routine testing and better treatment decisions?”
You can also read: COCOON: Lazertinib Lead-In Further Reduces Early Skin Toxicity With SC Amivantamab in EGFR-Mutant NSCLC
